Triple-negative breast cancer (TNBC) has special epidemiological and biological characteristics. Due to the lack of specific therapeutic targets, there is currently no standard chemotherapy regimen resulting in poor therapeutic response and dismal overall outcomes in the recurrence and metastasis stage. In recent years, with the continuous studies in terms of homologous recombination repair, tumor immunotherapy and new targeted drugs, certain achievements have been attained in the field of basic and clinical research concerning systemic treatment of advanced TNBC, which provide new insights for precise treatment of recurrent or metastatic TNBC.